Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Oncocross Co. Ltd. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 2 pending office actions. These actions are being handled by 2 distinct examiners across 2 distinct art units, reflecting a diverse range of perspectives on their applications. This distribution suggests that the company's biotechnology research is being evaluated by multiple experts within the Biotechnology & Pharmaceuticals field.
HAYES, JONATHAN EDWARD is the busiest examiner for the company, with 1 pending office action. Since there are 2 pending office actions in total, HAYES, JONATHAN EDWARD is responsible for 1 of the company's current workload. The distribution across 2 distinct art units shows that the company's innovations are being reviewed by more than one specialized group at the patent office, which can lead to different examination experiences for each application.
For the practitioner, having 2 distinct examiners and 2 distinct art units involved in 2 pending office actions requires a coordinated but flexible approach. Each application must be prosecuted according to the specific feedback from its examiner. The presence of 2 distinct art units also means that the company must be prepared to address the technical standards of different specialized divisions within the Biotechnology & Pharmaceuticals sector, ensuring that each case is handled with the appropriate technical focus.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAYES, JONATHAN EDWARD | 1 | 36.3% | +23.5% |
| RUIZ, JOSHUA DAMIAN | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17918977 | METHOD FOR ESTIMATING TISSUE-LEVEL INFORMATION FROM CELLULAR-LEVEL INFORMATION, AND DEVICE THEREFOR | RUIZ, JOSHUA DAMIAN | 14d |
| 18278887 | METHOD FOR DIAGNOSING CANCER OF UNKNOWN PRIMARY SITE BY USING ARTIFICIAL INTELLIGENCE | HAYES, JONATHAN EDWARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278887 | METHOD FOR DIAGNOSING CANCER OF UNKNOWN PRIMARY SITE BY USING ARTIFICIAL INTELLIGENCE | HAYES, JONATHAN EDWARD | — |
| Art Unit | Apps |
|---|---|
| 1685 | 1 |
| 3684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18278887 | METHOD FOR DIAGNOSING CANCER OF UNKNOWN PRIMARY SITE BY USING ARTIFICIAL INTELLIGENCE | HAYES, JONATHAN EDWARD | 1685 | §101§103§112 | Non-Final OA | — | Pending | Aug 25, 2023 |
| 17918977 | METHOD FOR ESTIMATING TISSUE-LEVEL INFORMATION FROM CELLULAR-LEVEL INFORMATION, AND DEVICE THEREFOR | RUIZ, JOSHUA DAMIAN | 3684 | §103 | Final Rejection | 14d | Pending | Oct 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOncocross Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jonathan Edward Hayes has the most, with 1 of Oncocross Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
